



**Media Releases » Torrent Pharma announces Q1 FY 14-15 results**  
*July 30th, 2014*

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th June, 2015. **Quarterly Financials**

Financial Highlights	Q1 FY 15	Q1 FY 14	Growth	Q1 FY 15	Q1 FY 14	Growth
Revenue	1,54	1,31	26%	5,87	5,07	15%
EBITDA	346	208	66%	1,56	1,03	51%
PAT (after Corporate taxes)	256	149	72%	89	25	256%
PAT (after Corporate taxes & minority interest)	206	124	67%	84	17	394%
EPS	12.2	6.8	79%	42	10.1	317%

- For Q1 FY 14-15 revenues were at Rs. 1,114 crores, up by 15% from Rs. 972 crores during the same period last year.
- EBITDA for Q1 FY 14-15 was at Rs. 346 crores up by 66% from Rs. 208 crores during the same period last year.

• PAT for the year (before minority interest) Q1 FY 14-15 was at Rs. 256 crores up by 72% compared to Rs. 149 crores during the same period last year.

**Performance Highlights of Q1 FY 15**

- Domestic formulation business recorded revenues of Rs. 356 crores, growing by 13%.
  - International revenues grew by 36% to Rs. 733 crores. Adjusting for currency movements revenues grew by 27%.
    - > Revenues from US operations recorded growth of 138%.
    - > Operations in Brazil registered revenue growth of 12%.
- Revenues from Europe (incl. Heumann) recorded a growth of 17%. Rest of the World including Russia & CIS operations recorded a de growth of 12%.

**Business Initiatives**

- During the quarter company consummated acquisition of Identified Indian Branded Formulations Business of Elder Pharmaceuticals Limited for a consideration of about Rs. 2000 cores.

**About Torrent Pharma**

Torrent Pharma, with an annual turnover of almost Rs. 4200 crores is the flagship Company of the Torrent Group. With many of its products ranking among the top 200 brands, Torrent continues to be at the forefront of the Indian pharmaceutical industry. Torrent has a fully equipped Research Center, employing almost 600 scientists, to support the Companies operations and product pipeline for both Domestic and Overseas markets. The Companies manufacturing plants located at Indrad, Baddi & Sikkim have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.